Controlled trial of a single dose of synthetic surfactant at birth in premature infants weighing 500 to 699 grams

David Stevenson, Frans Walther, Walker Long, Matthew Sell, Thomas Pauly, Alice Gong, David Easa, Arun Pramanik, Michael LeBlanc, Endla Anday, Ramasubbareddy Dhanireddy, David Burchfield, Anthony Corbet

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

In a multicenter, double-blind, placebo-controlled trial conducted at 23 hospitals in the United States, a single prophylactic 5 ml/kg dose of a synthetic surfactant (Exosurf Neonatal) or air placebo was administered shortly after birth to 215 infants with birth weights of 500 to 699 gm. Despite stratification at entry by birth weight and gender, by chance female infants predominated in the air placebo group and male infants predominated in the surfactant group. Among infants receiving synthetic surfactant, improvements in oxygen requirements were significant at 2 hours after birth (p=0.014) and persisted for 3 days (p=0.001); improvements in the alveolar-arterial partial pressure of oxygen gradient were significant at 6 hours after birth (p=0.01) and persisted for 3 days (p=0.008). Improvements in mean airway pressure were not significant at 2 or at 6 hours after birth (p=0.622 and 0.083, respectively), but became significant thereafter and persisted for 3 days (p=0.002). Pneumothorax was reduced by slightly more than half (25 vs 11; p=0.014); death from respiratory distress syndrome (RDS) was also reduced (26 vs 15; p=0.046). Overall neonatal mortality, however, was not significantly reduced (58 vs 46; p=0.102). Other complications of RDS and prematurity were not altered, except that pulmonary hemorrhage occurred significantly more frequently in infants receiving synthetic surfactant (2 vs 12; p=0.006). These findings indicate that a single prophylactic dose of synthetic surfactant in infants weighing 500 to 699 gm at birth improves lung function, incidence of air leak, and death from RDS but not overall mortality. The only safety problem identified was an increase in pulmonary hemorrhage.

Original languageEnglish (US)
JournalThe Journal of Pediatrics
Volume120
Issue number2 PART 2
DOIs
StatePublished - Jan 1 1992

Fingerprint

Premature Infants
Surface-Active Agents
Parturition
Air
Placebos
Birth Weight
Lung
Hemorrhage
Oxygen
Partial Pressure
Infant Mortality
Pneumothorax
Arterial Pressure
Safety
Pressure
Mortality
Incidence

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

Controlled trial of a single dose of synthetic surfactant at birth in premature infants weighing 500 to 699 grams. / Stevenson, David; Walther, Frans; Long, Walker; Sell, Matthew; Pauly, Thomas; Gong, Alice; Easa, David; Pramanik, Arun; LeBlanc, Michael; Anday, Endla; Dhanireddy, Ramasubbareddy; Burchfield, David; Corbet, Anthony.

In: The Journal of Pediatrics, Vol. 120, No. 2 PART 2, 01.01.1992.

Research output: Contribution to journalArticle

Stevenson, D, Walther, F, Long, W, Sell, M, Pauly, T, Gong, A, Easa, D, Pramanik, A, LeBlanc, M, Anday, E, Dhanireddy, R, Burchfield, D & Corbet, A 1992, 'Controlled trial of a single dose of synthetic surfactant at birth in premature infants weighing 500 to 699 grams', The Journal of Pediatrics, vol. 120, no. 2 PART 2. https://doi.org/10.1016/S0022-3476(05)81226-0
Stevenson, David ; Walther, Frans ; Long, Walker ; Sell, Matthew ; Pauly, Thomas ; Gong, Alice ; Easa, David ; Pramanik, Arun ; LeBlanc, Michael ; Anday, Endla ; Dhanireddy, Ramasubbareddy ; Burchfield, David ; Corbet, Anthony. / Controlled trial of a single dose of synthetic surfactant at birth in premature infants weighing 500 to 699 grams. In: The Journal of Pediatrics. 1992 ; Vol. 120, No. 2 PART 2.
@article{148e8f03e2ee455b8adca4e713ebedb4,
title = "Controlled trial of a single dose of synthetic surfactant at birth in premature infants weighing 500 to 699 grams",
abstract = "In a multicenter, double-blind, placebo-controlled trial conducted at 23 hospitals in the United States, a single prophylactic 5 ml/kg dose of a synthetic surfactant (Exosurf Neonatal) or air placebo was administered shortly after birth to 215 infants with birth weights of 500 to 699 gm. Despite stratification at entry by birth weight and gender, by chance female infants predominated in the air placebo group and male infants predominated in the surfactant group. Among infants receiving synthetic surfactant, improvements in oxygen requirements were significant at 2 hours after birth (p=0.014) and persisted for 3 days (p=0.001); improvements in the alveolar-arterial partial pressure of oxygen gradient were significant at 6 hours after birth (p=0.01) and persisted for 3 days (p=0.008). Improvements in mean airway pressure were not significant at 2 or at 6 hours after birth (p=0.622 and 0.083, respectively), but became significant thereafter and persisted for 3 days (p=0.002). Pneumothorax was reduced by slightly more than half (25 vs 11; p=0.014); death from respiratory distress syndrome (RDS) was also reduced (26 vs 15; p=0.046). Overall neonatal mortality, however, was not significantly reduced (58 vs 46; p=0.102). Other complications of RDS and prematurity were not altered, except that pulmonary hemorrhage occurred significantly more frequently in infants receiving synthetic surfactant (2 vs 12; p=0.006). These findings indicate that a single prophylactic dose of synthetic surfactant in infants weighing 500 to 699 gm at birth improves lung function, incidence of air leak, and death from RDS but not overall mortality. The only safety problem identified was an increase in pulmonary hemorrhage.",
author = "David Stevenson and Frans Walther and Walker Long and Matthew Sell and Thomas Pauly and Alice Gong and David Easa and Arun Pramanik and Michael LeBlanc and Endla Anday and Ramasubbareddy Dhanireddy and David Burchfield and Anthony Corbet",
year = "1992",
month = "1",
day = "1",
doi = "10.1016/S0022-3476(05)81226-0",
language = "English (US)",
volume = "120",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "2 PART 2",

}

TY - JOUR

T1 - Controlled trial of a single dose of synthetic surfactant at birth in premature infants weighing 500 to 699 grams

AU - Stevenson, David

AU - Walther, Frans

AU - Long, Walker

AU - Sell, Matthew

AU - Pauly, Thomas

AU - Gong, Alice

AU - Easa, David

AU - Pramanik, Arun

AU - LeBlanc, Michael

AU - Anday, Endla

AU - Dhanireddy, Ramasubbareddy

AU - Burchfield, David

AU - Corbet, Anthony

PY - 1992/1/1

Y1 - 1992/1/1

N2 - In a multicenter, double-blind, placebo-controlled trial conducted at 23 hospitals in the United States, a single prophylactic 5 ml/kg dose of a synthetic surfactant (Exosurf Neonatal) or air placebo was administered shortly after birth to 215 infants with birth weights of 500 to 699 gm. Despite stratification at entry by birth weight and gender, by chance female infants predominated in the air placebo group and male infants predominated in the surfactant group. Among infants receiving synthetic surfactant, improvements in oxygen requirements were significant at 2 hours after birth (p=0.014) and persisted for 3 days (p=0.001); improvements in the alveolar-arterial partial pressure of oxygen gradient were significant at 6 hours after birth (p=0.01) and persisted for 3 days (p=0.008). Improvements in mean airway pressure were not significant at 2 or at 6 hours after birth (p=0.622 and 0.083, respectively), but became significant thereafter and persisted for 3 days (p=0.002). Pneumothorax was reduced by slightly more than half (25 vs 11; p=0.014); death from respiratory distress syndrome (RDS) was also reduced (26 vs 15; p=0.046). Overall neonatal mortality, however, was not significantly reduced (58 vs 46; p=0.102). Other complications of RDS and prematurity were not altered, except that pulmonary hemorrhage occurred significantly more frequently in infants receiving synthetic surfactant (2 vs 12; p=0.006). These findings indicate that a single prophylactic dose of synthetic surfactant in infants weighing 500 to 699 gm at birth improves lung function, incidence of air leak, and death from RDS but not overall mortality. The only safety problem identified was an increase in pulmonary hemorrhage.

AB - In a multicenter, double-blind, placebo-controlled trial conducted at 23 hospitals in the United States, a single prophylactic 5 ml/kg dose of a synthetic surfactant (Exosurf Neonatal) or air placebo was administered shortly after birth to 215 infants with birth weights of 500 to 699 gm. Despite stratification at entry by birth weight and gender, by chance female infants predominated in the air placebo group and male infants predominated in the surfactant group. Among infants receiving synthetic surfactant, improvements in oxygen requirements were significant at 2 hours after birth (p=0.014) and persisted for 3 days (p=0.001); improvements in the alveolar-arterial partial pressure of oxygen gradient were significant at 6 hours after birth (p=0.01) and persisted for 3 days (p=0.008). Improvements in mean airway pressure were not significant at 2 or at 6 hours after birth (p=0.622 and 0.083, respectively), but became significant thereafter and persisted for 3 days (p=0.002). Pneumothorax was reduced by slightly more than half (25 vs 11; p=0.014); death from respiratory distress syndrome (RDS) was also reduced (26 vs 15; p=0.046). Overall neonatal mortality, however, was not significantly reduced (58 vs 46; p=0.102). Other complications of RDS and prematurity were not altered, except that pulmonary hemorrhage occurred significantly more frequently in infants receiving synthetic surfactant (2 vs 12; p=0.006). These findings indicate that a single prophylactic dose of synthetic surfactant in infants weighing 500 to 699 gm at birth improves lung function, incidence of air leak, and death from RDS but not overall mortality. The only safety problem identified was an increase in pulmonary hemorrhage.

UR - http://www.scopus.com/inward/record.url?scp=0026542111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026542111&partnerID=8YFLogxK

U2 - 10.1016/S0022-3476(05)81226-0

DO - 10.1016/S0022-3476(05)81226-0

M3 - Article

VL - 120

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 2 PART 2

ER -